BRISTOL-MYERS Squibb has agreed to pay US$670 million (Pounds 408 million) to settle numerous lawsuits after it was accused of using illegal tactics to keep lower-priced versions of its medicines, cancer-fighting Taxol and the anti-anxiety drug BuSpar, out of the market for many months. Both drugs are now available as generic medicines.


Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.